Department of Neurology, Leiden University Medical Center, Leiden, Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands.
Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4.
The Response Assessment in Neuro-Oncology-Patient-Reported Outcome (RANO-PRO) working group is an international multidisciplinary collaboration that provides guidance on the use of patient-reported outcome (PRO) measures in clinical trials and practice for adult patients with brain tumours. Findings from both PROs and traditional outcome measures, such as survival, and clinical or radiological response, are essential to inform the research community, policy makers, physicians, and patients in the treatment decision-making process. Previous initiatives in oncology have focused on guidelines concerning the collection, analysis, interpretation, and reporting of PRO data. However, we recommend the application of appropriate PRO instruments, with respect to its content and measurement properties (ie, research question, content validity, and other measurement properties), in brain tumour research. PROs should be well defined and reliable to generate high-quality evidence, and our recommendations on the use of specific PRO measures could help to improve the quality of PRO evidence derived from neuro-oncological studies, and might add a new dimension in how the value of therapeutics is assessed in patients with brain tumours. In this Policy Review, we present the RANO-PRO working plan for the use of PROs in adults with brain tumours.
神经肿瘤学患者报告结局评估(RANO-PRO)工作组是一个国际性的多学科合作组织,为成年脑肿瘤患者的临床试验和实践中使用患者报告结局(PRO)测量提供指导。PRO 和传统结局测量(如生存、临床或影像学反应)的结果对于告知研究界、政策制定者、医生和患者的治疗决策过程至关重要。肿瘤学以前的倡议侧重于关于 PRO 数据的收集、分析、解释和报告的指南。然而,我们建议在脑肿瘤研究中应用适当的 PRO 工具,考虑其内容和测量特性(即研究问题、内容有效性和其他测量特性)。PRO 应该是明确可靠的,以产生高质量的证据,我们对特定 PRO 措施的使用建议有助于提高源自神经肿瘤学研究的 PRO 证据的质量,并可能在如何评估脑肿瘤患者治疗药物的价值方面增加一个新维度。在本政策综述中,我们提出了 RANO-PRO 工作组在脑肿瘤成年患者中使用 PRO 的工作计划。